In a ruling dated yesterday, the Patent Trial and Appeal Board found that Geneoscopy proved Exact Sciences (EXAS)’ patent number 11,634,781, which is used for the company’s Cologuard colorectal cancer screening kits, are unpatentable. The tribunal wrote, “We conclude that Petitioner proves by a preponderance of the evidence that the challenged claims of the ‘781 patent are unpatentable.” The patent covers methods for collecting and preserving stool samples using separate buffers for blood and DNA tests, according to Bloomberg. Shares of Exact Sciences are down 3% to $53.68 following the ruling.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences’ Growth Potential Bolstered by Medicare Coverage and Strategic Investments
- Exact Sciences announces its Oncodetect MRD test receives Medicar coverage
- USPSTF ruling ‘marks the turn’ for Exact Sciences shares, says Evercore ISI
- USPSTF mandate being upheld a positive for Exact Sciences, says Leerink
- Supreme Court keeps element of Obamacare preventive care, Reuters reports